cigna glp 1 2025 requirements Wins First Cir. Bias Case Over Weight-Loss Drug Coverage Health insurer Cigna will stop
Description
advertising spend on GLP-1 drugs in the first nine months of 2025, while noting Canada enforces stricter direct-to-consumer drug advertising regulations [Source: cpha.ca/glp-1-agonists-and-obesity-public-health-perspective]
Effect of exenatide on the steady-state pharmacokinetics of digoxin
North America, particularly the US, is one of the largest markets for GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro
On the other hand, reduced sexual function while taking a GLP-1 drug could occur due to reward signaling in the brain, according to Balazs
This dual action enhances appetite control, reduces food noise more intensely, and leads to greater overall weight loss
